Since Bio-Rad launched ddPCR over 13 years ago, liquid biopsy has revolutionized cancer treatment, enabling immediate adoption in research and providing clinicians with crucial information for therapeutic decisions through advanced technologies and extensive research. We are inviting researchers who are exploiting ddPCR to advance cancer research and help select better treatments for patients. We will show how accurate cfDNA analysis can improve stratification for more effective therapy management. Additionally, we will discover how CTC-derived gDNA can be an unexpected source of additional information, indicating that complementary information from plasma-cfDNA and CTC-derived gDNA could improve therapy selection.
| Time | Session |
|---|
|
13:30
13:35
|
Introduction
|
|
13:35
13:50
|
Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer
|
|
13:50
14:05
|
Detection rate for ESR1 mutations is higher in CTC-derived genomic DNA than in paired plasma cell-free DNA samples as revealed by ddPCR
|
|
14:05
14:15
|
Questions and Answers
|